DBD(DBD)
DBD
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E |
|---|---|---|
| Revenue Avg | $3.89B | $4.04B |
| Low | $3.87B | $4.00B |
| High | $3.91B | $4.08B |
| EBITDA Avg | $605M | $627M |
| Low | $602M | $621M |
| High | $608M | $633M |
| EBIT Avg | $493M | $512M |
| Low | $491M | $506M |
| High | $496M | $517M |
| Net Income Avg | $204M | $253M |
| Low | $202M | $236M |
| High | $207M | $269M |
| EPS Avg | $5.49 | $6.79 |
| Low | $5.44 | $6.34 |
| High | $5.55 | $7.24 |
| Analysts (Rev / EPS) | 2 / 2 | 2 / 2 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 |
|---|---|---|---|---|---|---|
| Revenue Avg | $972M | $1.12B | $916M | $963M | $999M | $1.13B |
| Low | $969M | $1.12B | $912M | $960M | $995M | $1.13B |
| High | $975M | $1.13B | $918M | $966M | $1.00B | $1.13B |
| EBITDA Avg | $151M | $175M | $142M | $150M | $155M | $176M |
| Low | $151M | $174M | $142M | $149M | $155M | $175M |
| High | $151M | $175M | $143M | $150M | $156M | $176M |
| EBIT Avg | $123M | $143M | $116M | $122M | $127M | $143M |
| Low | $123M | $142M | $116M | $122M | $126M | $143M |
| High | $124M | $143M | $116M | $122M | $127M | $144M |
| Net Income Avg | $52M | $81M | $40M | $54M | $62M | $91M |
| Low | $52M | $81M | $40M | $54M | $62M | $90M |
| High | $52M | $81M | $40M | $55M | $62M | $91M |
| EPS Avg | $1.45 | $2.27 | $1.13 | $1.52 | $1.74 | $2.54 |
| Low | $1.44 | $2.26 | $1.12 | $1.52 | $1.73 | $2.53 |
| High | $1.46 | $2.27 | $1.13 | $1.53 | $1.75 | $2.55 |
| Analysts (Rev / EPS) | 2 / 2 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 |